Real world evidence

OneMedNet Announces Participation as an Exhibitor at the 15ᵗʰ Annual SCOPE Summit

Retrieved on: 
Monday, January 29, 2024
RWD, Patient, SCOPE, Research, Artificial intelligence, Booth, Leverage, Chin Na, Real world evidence, Generating, Real, Clinical trial

MINNEAPOLIS, Jan. 29, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade imaging Real World Data (“iRWD”), today announced its participation as an exhibitor at the 15th Annual SCOPE Summit for Clinical Ops Executive (the “SCOPE Summit”) being held February 11-14, 2024 in Orlando, FL.

Key Points: 
  • MINNEAPOLIS, Jan. 29, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade imaging Real World Data (“iRWD”), today announced its participation as an exhibitor at the 15th Annual SCOPE Summit for Clinical Ops Executive (the “SCOPE Summit”) being held February 11-14, 2024 in Orlando, FL.
  • The 2024 SCOPE Summit will feature two Real World Evidence tracks that highlight the critical importance and innovative science and technology of this specialized data: Accessing and Generating RWD and Leveraging RWD for Clinical Research and Observational Research.
  • To learn more about OneMedNet and its Real World Data Solution, please visit www.onemednet.com .
  • The annual SCOPE Summit is the industry's most impactful conference exclusively focused on connecting clinical trial operations executives who are actively seeking new technology to improve the experience for patients, sites, and study teams.

New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease

Retrieved on: 
Wednesday, January 10, 2024
Diabetes, RWE, American Heart Association, Patient, Diabetic nephropathy, Kidney, MD, Hypertension, Risk assessment, Type 2 diabetes, Insurance, Heart failure, Risk, Food, Chronic kidney disease, Real world evidence, CKD, Community health, FDA, Doctor of Philosophy, BMI, Real, EGFR, Marketing, Physician, Pharmaceutical industry

LONDON and SALT LAKE CITY, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces publication of Real World Evidence (“RWE”) after 12 months of follow-up in 2,569 patients with Type 2 diabetes and diabetic kidney disease (“DKD”) at a major U.S. health system in Primary Care and Community Health. Results in the diverse cohort, including 27% black patients, demonstrate that electronic health record deployment of KidneyIntelX in vitro prognostic testing was associated with clinical actions that led to a significant slowing of chronic kidney disease progression and improved Type 2 diabetes control most notably in the highest risk patients.

Key Points: 
  • Improved kidney health was evidenced by reduction in the rate of kidney function decline (eGFR slope) and diabetes control was evidenced by improved A1C levels.
  • KidneyIntelX testing achieved scale through electronic health record integration, deploying directly to large treating groups of primary care physicians.
  • KidneyIntelX has received broad insurance payment coverage including through Medicare, Medicaid, and Blue Cross Blue Shield programs.
  • “The demonstrated benefits of KidneyIntelX early risk assessment at one year are significant and go to the core of chronic disease preventative medicine.

Klick Health Creates Generative AI Tool to Eliminate Common Advertising Agency Groundhog Day Scenarios

Retrieved on: 
Thursday, November 16, 2023
Data Management, Technology, Diabetes, Health, General Health, Advertising, Communications, Health Technology, Software, Artificial Intelligence, Internet, Human, Research, Genome, Real, Click, Groundhog Day (film), Real world evidence, History, Multimedia, Checklist, Medicine, Nature, Information system, Artificial intelligence, Machine learning, Automation, The New York Times, ChatGPT, SVP, Mayo Clinic Proceedings, AI, Digital health, News, Type 2 diabetes, RWE, Medical device, Sales, Risk management

Klick Health today announced Genome Perspective, the first artificial intelligence (AI) tool to be developed by an advertising agency to expedite project planning and increase the efficiency and velocity of delivery to clients.

Key Points: 
  • Klick Health today announced Genome Perspective, the first artificial intelligence (AI) tool to be developed by an advertising agency to expedite project planning and increase the efficiency and velocity of delivery to clients.
  • View the full release here: https://www.businesswire.com/news/home/20231116971568/en/
    Klick Health has created Genome Perspective, the first artificial intelligence (AI) tool to be developed by an advertising agency to expedite project planning and increase the efficiency and velocity of delivery to clients.
  • The questions are hierarchically arranged, and the tool is sophisticated enough to traverse through only those that are relevant to the specific project.
  • Unlike other generative AI tools, which only generate new content, Genome Perspective was created to understand content and advance it in a practical way.

World Healthcare Data Research Report 2023: Market to Triple by 2030 - New Entrants and Incumbents are Leveraging RWD/RWE to Generate Valuable Insights

Retrieved on: 
Monday, November 13, 2023
Real-World Evidence, Drug development, Acquisition, Real, Organization, Health policy, Real world evidence, Electronic health record, RWD, Public health surveillance, Ecosystem, Health information management, Procurement, COVID-19, Flatiron, Evidence, RWE, Research report, Pharmaceutical industry, Sales, Research

The report provides valuable insights into the current and future state of the RWD/RWE market.

Key Points: 
  • The report provides valuable insights into the current and future state of the RWD/RWE market.
  • These trends are leading to a rapidly growing market, which this report forecasts will experience an average 14.6% CAGR through 2030, roughly tripling today's addressable market from $4.6B to $13.6B USD.
  • The research is relevant to any healthcare stakeholder looking to leverage real-world data for evidence-based decision making.
  • The mass digitization of healthcare records over the past decade has led to an explosion of new, highly-valued clinical data assets.

Folia Health Announces Groundbreaking Flare Tracking Technology to Bridge Research Gaps and Enhance Chronic Condition Management

Retrieved on: 
Thursday, November 9, 2023
Patient, Health care, MPH, NIH Intramural Research Program, Real world evidence, Sickle cell disease, Real world data, Conditional sentence, Health, Quality of life, Research, RWE, Real, Predictive analytics, Algorithm, Nursing, Pharmaceutical industry, Flare

Folia Health's Flare Tracking Technology provides an innovative solution that reimagines the horizon of acute event management, improving patient care and contributing to vital research endeavors.

Key Points: 
  • Folia Health's Flare Tracking Technology provides an innovative solution that reimagines the horizon of acute event management, improving patient care and contributing to vital research endeavors.
  • 3) Bridging Research Gaps: By analyzing Flare data between clinic visits, Folia Health's technology contributes to the wealth of Real World Evidence (RWE), improving our understanding of chronic diseases and refining treatment strategies.
  • Nell Meosky Luo, Chief Executive Officer and Founder at Folia Health, commented, “Our Flare Tracking Technology represents a significant step forward in the understanding of chronic diseases.
  • To learn more about Folia Health's Flare Tracking Technology and its dual impact on chronic disease management and research, please visit https://www.foliahealth.com/research or reach out to [email protected] .

Introducing Cercle - AI Bridging the Gap in Women's Healthcare

Retrieved on: 
Wednesday, November 8, 2023
Fertility, Knowledge, Woman, FDA, RWD, Roger Hawkins (drummer), Copenhagen, HIPAA, Real world evidence, Genetics, Congress, Medtech, USF, RWE, Research, University of Copenhagen Faculty of Health and Medical Sciences, IVF, Genomics, Real, Medicine, Partnership, University, Privacy, Clinic, AI, Real world data, Patient, Acceleration, Medical imaging, Medical device, Nursing, Cercle

SAN FRANCISCO, Nov. 8, 2023 /PRNewswire/ -- Cercle, an AI technology company unlocking comprehensive and secure data insights for the healthcare industry, announced its launch today. Its technology platform, the Cercle™ Biomedical Graph, is the first and only of its kind, harnessing and connecting billions of anonymized biomedical and genomics data points drawn securely from healthcare clinics and research labs around the world. When channeled through the Cercle™ Biomedical Graph, these data points become a treasure trove of insights for clinics, medical researchers, healthcare providers, patients, and the rest of the healthcare  ecosystem. These data insights can accelerate medical discoveries in the pharmaceutical and research fields, enable the acceleration of precision medicine and personalized treatments, help clinics improve the efficiency and effectiveness of  medical care, and ultimately, drive better health outcomes. The company has already partnered with two trusted healthcare institutions, Eurofins Genoma and US Fertility.

Key Points: 
  • When channeled through the Cercle™ Biomedical Graph, these data points become a treasure trove of insights for clinics, medical researchers, healthcare providers, patients, and the rest of the healthcare  ecosystem.
  • Cercle is launching first in fertility and women's healthcare, ushering in a new age of accuracy, knowledge and clarity in a historically under-researched and under-funded medical field.
  • Cercle utilizes AI technology to harmonize and transform this raw and fragmented data into accurate insights that help improve patient outcomes.
  • Cercle plans to support doctors, clinics, biotech and pharmaceutical researchers, and healthcare communities across many women's healthcare verticals and needs beyond fertility in the future.

Atropos Health Launches New Geneva OS and ChatRWD User Application for Rapid Real World Evidence With Generative AI

Retrieved on: 
Thursday, October 5, 2023
Data Management, Practice Management, Technology, Professional Services, Health, Health Technology, Research, Data Analytics, Software, Artificial Intelligence, Science, Multimedia, Chin Na, Real world evidence, Real world data, Doctor of Philosophy, Internet, Real, MBBS, Organization, Ethics, OS, Roger Hawkins (drummer), Safety, Stanford University, Stanford University Medical Center, Entrepreneurship, Synthetic media, ChatGPT, Chat, Literature, ROI, The New York Times, Patient, Mobile phone, Nursing, Medicine

Atropos Health , leader in evidence generation for healthcare, today announced the launch of the Geneva OS™(Generative Evidence Acceleration Operating System) and the ChatRWD™ (Real World Data) application, the first Generative AI application incorporating direct Chat-to-Database capability, to help healthcare and life science leaders advance and accelerate evidence generation.

Key Points: 
  • Atropos Health , leader in evidence generation for healthcare, today announced the launch of the Geneva OS™(Generative Evidence Acceleration Operating System) and the ChatRWD™ (Real World Data) application, the first Generative AI application incorporating direct Chat-to-Database capability, to help healthcare and life science leaders advance and accelerate evidence generation.
  • “In addition, our ChatRWD user application represents an evolutionary jump in the speed and user experience by which evidence can be generated.
  • Users can now access Geneva OS and ChatRWD alongside Atropos’ existing evidence solutions – the Green Button Informatics Consult Service, Atropos Evidence Network, and Atropos Evidence Library.
  • Existing Atropos Health users are already receiving access to Geneva OS and the company is accepting beta users for the ChatRWD application.

Policlinico Gemelli and Palantir Technologies Partner to Use AI to Advance Data Science for Healthcare

Retrieved on: 
Friday, September 8, 2023
Science, Software, Research, Health, Artificial Intelligence, Data Management, Health Technology, Technology, Real, Partnership, Intelligence, RWD, Generator, Traction, PLTR, Palantir Technologies, Foundry, AI, MAK Technologies, Inc., NYSE, Real world evidence, Medical device, Palantir

Palantir Technologies Inc. (NYSE: PLTR) (“Palantir”) and Gemelli Generator Real World Data (RWD), a research facility of Fondazione Policlinico Universitario A. Gemelli IRCCS (“Policlinico Gemelli”), today announced a partnership to implement digital medicine research solutions that leverage artificial intelligence to improve patient care and health outcomes.

Key Points: 
  • Palantir Technologies Inc. (NYSE: PLTR) (“Palantir”) and Gemelli Generator Real World Data (RWD), a research facility of Fondazione Policlinico Universitario A. Gemelli IRCCS (“Policlinico Gemelli”), today announced a partnership to implement digital medicine research solutions that leverage artificial intelligence to improve patient care and health outcomes.
  • Policlinico Gemelli’s digital research center, Generator RWD, will utilize Palantir Foundry as one of the key enabling platforms to manage the full scale and complexity of healthcare data.
  • Palantir’s software will boost the capabilities of Generator RWD and its partner network as they continue in their quest to strengthen the exploitation of data to gain new insights in several healthcare research domains.
  • “Healthcare is transforming through the power of data and AI, and this trend will only accelerate.

From HITECH to the COVID-19 PHE: These Real-World Data Technologies are Helping Define Evidence-Based Care

Retrieved on: 
Wednesday, August 30, 2023
Real-World Evidence, Cosmos, Komodo, Real, Research report, Drug development, Procurement, Thermo Fisher Scientific, Real world evidence, COVID-19, RWD, Electronic health record, Health policy, Organization, Evidence, Aetion, Acquisition, RWE, Health Information Technology for Economic and Clinical Health Act, Carev Dvor, Ecosystem, Public health surveillance, Health information management, Pharmaceutical industry, IQVIA, Tempus, Research

'Real-world data' (RWD) has been used in a variety of research purposes to develop 'real-world evidence' (RWE) for decades, but never to the extent that is occurring today.

Key Points: 
  • 'Real-world data' (RWD) has been used in a variety of research purposes to develop 'real-world evidence' (RWE) for decades, but never to the extent that is occurring today.
  • However, nearly 80% of healthcare data is still in unstructured formats, necessitating specialized solutions that can help process this data so it can be applied effectively.
  • "By working together, they can overcome barriers such as data fragmentation, data quality concerns, and regulatory uncertainties.
  • The research is relevant to any healthcare stakeholder looking to leverage real-world data for evidence-based decision making.

Stallergenes Greer Showcases Clinical Relevance and Persisting Benefits of Its Allergen Immunotherapy Treatments at 2023 EAACI Congress

Retrieved on: 
Friday, June 9, 2023
Biotechnology, General Health, Other Health, Health, Cardiology, Real, European Academy of Allergy and Clinical Immunology, Abstract, International, AIT, RCT, EAACI, Patient, Congress, Allergy, Allergen, Medicine, Patient-reported outcome, Real world evidence, Pharmaceutical industry

Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy (AIT), will be hosting a company-sponsored symposium entitled “Patient’s perspective: A must have for the future of Allergen Immunotherapy” at the 2023 European Academy of Allergy and Clinical Immunology (EAACI) Congress taking place June 9-11 in Hamburg (Germany).

Key Points: 
  • Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy (AIT), will be hosting a company-sponsored symposium entitled “Patient’s perspective: A must have for the future of Allergen Immunotherapy” at the 2023 European Academy of Allergy and Clinical Immunology (EAACI) Congress taking place June 9-11 in Hamburg (Germany).
  • During the symposium, four of the world’s leading experts in respiratory allergy will showcase advancements regarding the clinical relevance of its AIT treatments, which contribute to furthering precision medicine and enhance patient benefits.
  • “Stallergenes Greer is committed to therapeutic progress to meet the needs of patients and the medical community.
  • During the congress, Stallergenes Greer will also present 13 abstracts on precision medicine in AIT and patient benefits and announce new data from clinical trials (EfficAPSI, Practis, and long-term data generated in Japan).